Abiraterone acetate (AA) is a potent, selective androge (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA).
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety / Fabbri, M. A.; Cortesi, E.; Marchetti, Paolo; Santini, D.; Gamucci, T.; Angelini, F.; Longo, F.; Milano, Annalisa; Mancini, M. L.; Giuli, A.; Quadrini, S.; Sperduti, I.; Pellegrino, A.; Ratta, R.; Primi, F.; Chilelli, M. G.; Ruggeri, E. M.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - ELETTRONICO. - 51:3(2015), pp. 490-490. (Intervento presentato al convegno European Cancer Congress tenutosi a Wien Austria) [10.1016/S0959-8049(16)31363-6].
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety
E. Cortesi;MARCHETTI, PAOLO;D. Santini;MILANO, ANNALISA;
2015
Abstract
Abiraterone acetate (AA) is a potent, selective androge (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA).| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabbri_ Abstract-2544-Abiraterone_2015.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
49.94 kB
Formato
Adobe PDF
|
49.94 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
